Dr. Lerner gives highlights of SUO’s 2021 bladder cancer course
“The idea was really to bring together a multidisciplinary group of experts and to discuss…highly relevant, translational research that’s going on, and to…address some of the really critical clinical questions as well,” says Seth P. Lerner, MD, FACS.
In this video, Seth P. Lerner, MD, FACS, discusses the key points of the bladder cancer course presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Lerner is a professor of urology, Beth and Dave Swalm Chair in urologic oncology, director of urologic oncology, and director of the Multidisciplinary Bladder Cancer Program at the Baylor College of Medicine, Houston, Texas.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
